A Phase 1 Open-label Study in Healthy Subjects to Assess the Relative Oral Bioavailability and Food Effect of Single-dose JNJ-64417184 Administered as Tablets and as Suspension
Latest Information Update: 26 Sep 2019
At a glance
- Drugs JNJ-64417184 (Primary) ; JNJ-64417184
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 23 Sep 2019 Status changed from recruiting to completed.
- 11 Jun 2019 Status changed from not yet recruiting to recruiting.
- 20 May 2019 Planned initiation date changed from 10 May 2019 to 15 May 2019.